Answers are grounded in this paper and cite their sources.
In interventional studies, the risk of serious infections with tofacitinib is comparable to published rates for biologic disease-modifying antirheumatic drugs in patients with moderate to severely active RA.
No takes yet. Share an insight, caveat, or question.
Strand et al. (2015) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: